The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. As a descendent of the BA.3 omicron subvariant that emerged in 2022, it has since raised alarms due to its significant number of mutations. Specifically, Cicada carries approximately 70 to 75 mutations in its spike protein, which is a crucial aspect of the virus that allows it to infect human cells.

As the variant spreads, it has been detected in over 20 countries, including 25 states in the United States, where its presence is currently on the rise. Health authorities are actively monitoring the BA.3.2 variant due to its increasing prevalence and the potential implications for public health. Initial observations suggest that most cases of the Cicada variant appear mild to moderate, resembling flu-like illness, particularly among vaccinated individuals.

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. Despite the variant’s mutations, health experts emphasize that symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains, with no new or unusual signs reported so far.

Dr. Adolfo García-Sastre, a prominent figure in infectious disease research, stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This sentiment is echoed by many health professionals who note that most cases can be managed at home with rest and hydration. Current evidence suggests that BA.3.2 does not cause more severe illness compared to earlier variants, which is a relief for many as the world continues to navigate the pandemic.

Vaccination remains a critical tool in combating the spread of the Cicada variant. While the current COVID-19 vaccines may not be as effective against it due to the multiple mutations, they are still expected to provide strong protection against severe disease, even if breakthrough infections occur. Health experts recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the risk of transmission.

As the variant continues to spread, health authorities are urging the public to remain vigilant. Observers anticipate that with ongoing monitoring and vaccination efforts, the impact of the Cicada variant can be managed effectively. However, the situation remains fluid, and details regarding the variant’s behavior and impact continue to evolve.

In summary, while the Cicada variant presents new challenges due to its mutations and spread, the symptoms it causes are largely similar to those of earlier strains. The focus remains on vaccination and public health measures to curb its transmission and protect vulnerable populations.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on NewsNationIndia.

As the world continues to grapple with the COVID-19 pandemic, a new variant known as the Cicada variant has emerged, drawing attention for its significant number of mutations. This variant, classified as BA.3.2 and part of the Omicron family, was first spotted in South Africa in November 2024.

By early 2025, the Cicada variant began to spread to various countries, including India, where health officials are closely monitoring its impact. The variant carries approximately 75 mutations, with over 50 of these located in the spike protein, which is critical for the virus’s ability to infect human cells.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. These symptoms are similar to those of previous variants, raising questions about the variant’s severity.

Currently, there is no confirmed evidence that the Cicada variant causes more severe illness than earlier strains. However, real-world data on the severity of illness caused by this variant is still limited, leaving health experts cautious.

In the United States, the first confirmed case of the Cicada variant was reported in June 2025, with three patients confirmed by January 2026, all of whom recovered. This indicates that while the variant is spreading, it may not necessarily lead to increased hospitalizations.

Dr. Robert Hopkins Jr. has noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This statement underscores the uncertainty surrounding the variant’s potential to outpace others.

The Centers for Disease Control and Prevention (CDC) has emphasized the importance of monitoring the spread of BA.3.2, stating that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.

As of now, the Cicada variant has been detected in 22 countries, prompting global health authorities to remain vigilant. The situation is fluid, and health officials in India and elsewhere are preparing for various scenarios as they assess the variant’s implications.

The emergence of the Cicada variant highlights the ongoing challenges posed by COVID-19 and the need for continued surveillance and research. As the world adapts to new variants, understanding their characteristics and effects will be crucial for public health responses.

Details remain unconfirmed.

The post Cicada COVID Variant in India: A Deep Dive into Its Emergence and Implications appeared first on NewsNationIndia.